歌礼制药有限公司（股票代码：01672）于2026年10月29日发布翌日披露报表，公告显示，公司在香港联交所场内回购普通股10万股，约占当日已发行股本0.0095%。回购价格区间介乎每股5.185港元至5.305港元，总耗资约52.54万港元。
公告称，回购完成后，公司已发行股本维持在1,052,202,859股，库藏股数量则保持5,784,210股。同时，歌礼制药-B已于2026年6月29日通过回购授权，授权总数为106,137,084股。截至目前，公司在香港联交所或其他证券交易所合计回购股份5,195,000股，占回购授权时已发行股本的约0.4895%。公司确认已遵守相关上市规则及适用法规。上述公告由公司秘书钟明辉签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.